1. Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy 11-dehydrocortisone), compound E and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 24: 181-197, 1949.
2. Liapi C, Chrousos GP. Glucocorticoids. In: Jaffe SJ, Aranda JV (eds) Pediatric Pharmacology, 2nd Edition, WB Saunders Co, Philadelphia, pp. 466-475, 1992.
3. Tyrell JB, Baxter JD. Glucocorticoid therapy. In: Felig P, Baxter JB, Broadus AE (eds) Endocrinology and Metabolism, 2nd Edition, McGraw-Hill, New York, pp. 788-817, 1987.
4. Axelrod L. Glucocorticoid therapy. Medicine 55: 39-65, 1976.
5. Christy NP. Pituitary-adrenal function during corticosteroid therapy: learning to live with uncertainty (editorial). N Engl J Med 326: 266-267, 1992.
6. Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA 282: 671-676, 1999.
7. Rimsza ME. Complications of corticosteroid therapy. Am J Dis Child 132: 806-810, 1978.
8. Melby JC. Systemic corticosteroid therapy: pharmacology and endocrinologic considerations. Ann Intern Med 81: 505-512, 1974.
9. Pousseau GG, Baxter JD, Tomkins GP. Glucocorticoid receptor: relation between steroid binding and biologic effects. J Mol Biol 67: 99-115, 1972.
10. Magiakou MA, Chrousos GP. Corticosteroid therapy, nonendocrine disease and corticosteroid withdrawal. In: Bardin CW (ed) Current Therapy in Endocrinology and Metabolism, 5th Edition, Mosby Yearbook, Philadelphia, pp. 120-124, 1994.
11. Laue L, Kawai S, Udelsman R, et al. Glucocorticoid antagonists: pharmacological attributes of the prototype antiglucocorticoid RU 486. In: Lichtenstein LM, Claman H, Oronsky A (eds) Antiinflammatory Steroid Action: Basic and Clinical Aspects, New York: Academic Press, pp. 303-329, 1989.
12. Orth DN. Adrenal insufficiency. In: Bardin CW (ed) Current Therapy in Endocrinology and Metabolism, 5th Edition, Mosby Yearbook Inc, St Louis, pp. 124-130, 1994.
13. Clark JH, Schrader WT, O'Malley BW. Mechanisms of action of steroid hormones. In: Wilson JD, Foster DW (eds) Williams Textbook of Endocrinology, WB Saunders Co, Philadelphia, pp. 35-90, 1992.
14. Magiakou MA, Chrousos GP. Corticosteroid therapy and withdrawal. In: Endocrinology and Metabolic Diseases, Current Practice of Medicine, Philadelphia, pp. IV: 6.1-6.6, 1996.
15. Boumpas DT, Chrousos GP, Wilder Rl, et al. NIH conference of the combined clinical staff. Glucocorticoid therapy of immune-related diseases: basic and clinical correlates. Ann Intern Med 119: 1198-1208, 1993.
16. Harter JG. Corticosteroids: their physiologic use in allergic disease. N Y State J Med 66: 827-840, 1966.
17. Castilla C, Perez-Simon JA, Sanchez-Guijo FM, etal. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). Biol Blood Marrow Transplant. 12:936-41, 2006
18. Iyer RV, Hahn T, Roy HN, et al.Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease.Biol Blood Marrow Transplant. 11:587-592, 2005.
19. Rix M, Birkebaek NH, Rosthoj S, Clausen N.Clinical impact of corticosteroid-induced adrenal suppression during treatment for acute lymphoblastic leukemia in children: a prospective observational study using the low-dose adrenocorticotropin test. J Pediatr. 147:645-650,2005.
20. Raitt DG, Merrifield AJ. Dexamethasone in malignant hyperpyrexia (letter). Br Med J 4: 656, 1974.
21. Salerno A, Hermann R.Efficacy and safety of steroid use for postoperative pain relief. Update and review of the medical literature. J Bone Joint Surg Am. 88:1361-1372, 2006.
22. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of the respiratory distress syndrome. Am J Obstet Gynecol 141: 276-286, 1981.
23. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 280: 159-165, 1998.
24. Chrousos GA, Kattah JC, Beck RW, et al. Side effects of glucocorticoid treatment. Experience of the optic neuritis treatment trial. JAMA 269: 2110-2112, 1993.
25. Carella MJ, Srivastava LS, Gossain VV, Rovner DR. Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy. J Clin Endocrinol Metab 76: 1188-1191, 1993.
26. Streck WF, Lockwood DH. Pituitary adrenal recovery following short-term suppression with corticosteroids. Am J Med 66: 910-914, 1979.
27. Kamilaris T, Chrousos GP. Cushing's syndrome. In: Rakel R (ed) Conn's Current Therapy. WB Saunders Co, Philadelphia, pp. 572-578, 1991.
28. Morris HG. Growth and skeletal maturation in asthmatic children: effect of corticosteroid treatment. Pediatr Res 9: 579-583, 1975.
29. Black RL, Oglesby RB, von Sallmann L, et al. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 174: 166-171, 1960.
30. Haanaes OC, Bergmann A. Tuberculosis emerging in patients treated with corticosteroids. Eur J Respir Dis 64: 294-297, 1983.
31. Rokicki W, Bertrand J. The glucocorticoids in normal premature and small for dates newborn infants throughout the neonatal period. In: Stern L, Salle B, Friis-Hansen B (eds) Intensive Care of the Newborn, 2nd Edition, Masson, New York, pp. 325-342, 1981.
32. Hebert AA, Friedlander SF, Allen DB.Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr. 149:378-382, 2006.
33. Ozon A, Cetinkaya S, Alikasifoglu A, Gonc EN, Sen Y, Kandemir N.Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab. 20:219-225, 2007.
34. Kwinter J, Pelletier J, Khambalia A, Pope E.High-potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol. 56:236-241, 2007.
35. Schlessinger J, Miller B, Gilbert RD, Plott RT; Vanos Study Group.An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis. Arch Dermatol. 142:1568-1572, 2006.
36. Andres P, Poncet M, Farzaneh S, Soto P.Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.J Drugs Dermatol. 5:328-332, 2006.
37. Reid DC, Kimball AB.Clobetasol propionate foam in the treatment of psoriasis.Expert Opin Pharmacother. 6:1735-1740, 2005.
38. Todd G R G, Acerini C L, Ross-Russell R, Zahra S, Warner J T, McCance D. Survey of adrenal crisis associated with inhaled costicosteroids in the United Kingdom. Arch Dis Child 87:457-461, 2002.
39. Zollner EW.Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids: part 1. Which test should be used?Pediatr Allergy Immunol. 18:401-409, 2007.
40. ZöllnerEW. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids (Part 2)--the risk as determined by gold standard adrenal function tests: a systematic review. Pediatr Allergy Immunol. 18:469-474, 2007.
41. Gulliver T, Morton R, Eid N.Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations.Paediatr Drugs. 9:185-194, 2007.
42. Allen DB.Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr. 53:101-110, 2006.
43. Priftis KN, Papadimitriou A, Anthracopoulos MB, et al.Adrenal function improves in asthmatic children on inhaled steroids: a longitudinal study. Neuroimmunomodulation.13:56-62, 2006.
44. Dahl R.Systemic side effects of inhaled corticosteroids in patients with asthma.Respir Med. 100:1307-1317, 2006.
45. Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D.Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest. 128:1104-1114. 2005.
46. Langdon CG, Adler M, Mehra S, Alexander M, Drollmann A.Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med. 99:1275-1285, 2005.
47. Liu EA, Heldt GP. A trial of the safety of inhaled beclomethasone in ventilator-treated neonates. J Pediatr 129: 154-156, 1996.
48. Cole CA, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 340: 1005-1010, 1999.
49. Ng PC, Fok TF, Wong GWK, et al. Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment. J Clin Endocrinol Metab 83: 2390-2393, 1998.
50. Cole CA, Shah B, Abbasi S, et al. Adrenal function in premature infants during inhaled beclomethasone therapy. J Pediatr 135: 65-70, 1999.
51. DelGaudio JM, Wise SK.Topical steroid drops for the treatment of sinus ostia stenosis in the postoperative period. Am J Rhinol. 20:563-567, 2006.
52. Gulliver T, Eid N.Effects of glucocorticoids on the hypothalamic-pituitary-adrenal axis in children and adults. Immunol Allergy Clin North Am. 25:541-555, 2005.
53. Hameed R, Zacharin MR.Cushing syndrome, adrenal suppression and local corticosteroid use. J Paediatr Child Health. 42:392-394, 2006.
54. Messer J, Reitman D, Sacks HC, et al. Association of adrenocorticosteroid therapy and peptic ulcer disease. N Engl J Med 309: 21-24, 1983.
55. Ackerman GL, Nolan CM. Adrenocortical responsiveness after alternate-day corticosteroid therapy. N Engl J Med 278: 405-409, 1968.
56. Nichols T, Nugent CA, Tyler FH. Diurnal variation in suppression of adrenal function by glucocorticoids. J Clin Endocrinol 25: 343-349, 1965.
57. Jasani MK, Boyle JA, Greig WR, et al. Corticosteroid-induced suppression of the hypothalamo-pituitary-adrenal axis: observations on patients given oral corticosteroids for rheumatoid arthritis. QJM 36: 261-276, 1967.
58. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 326: 226-230, 1992.
59. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal axis in patients with rheumatoid diseases receiving lowdose prednisone. Am J Med 95: 258-264, 1993.
60. Amatruda TT Jr, Hollingsworth DR, D' Esopo ND, Upton GV, Bondy PK. A study of the mechanism of the steroid withdrawal syndrome: evidence for integrity of the hypothalamic-pituitary-adrenal system. J Clin Endocrinol Metab 20: 339-354, 1960.
61. Ozbek OY, Turktas I, Bakirtas A, Bideci A.Evaluation of hypothalamic-pituitary-adrenal axis suppression by low-dose (0.5 microg) and standard-dose (250 microg) adrenocorticotropic hormone (ACTH) tests in asthmatic children treated with inhaled corticosteroid. J Pediatr Endocrinol Metab. 19:1015-1023, 2006.